## Summary of evidence and Expert Committee recommendations

Allopurinol was included on the complementary list of the first EMLc in 2007. The EMLc Subcommittee considered that allopurinol was necessary for management of children within oncology practice and that it should be included in cytotoxics and adjuvant medicines section of the EMLc for this indication.